CLINICAL NEWS
Most current hospital readmission risk prediction models that were designed for either comparative or clinical purposes perform poorly. The findings were reported in the October 19 issue of the Journal of the American Medical Association. » More
|
|
The first results from an ongoing phase 3 trial of RTS,S/AS01 show it provides African children with significant protection against clinical and severe malaria. The results were published online October 18 in the New England Journal of Medicine. » More |
|
The AAP recently issued updated guidelines to help diagnose and treat ADHD in younger children and adolescents. » More |
Survey
a) We follow the CMS-approved compendia. If a medication is listed, it is approved. We do not follow any pathway.
b) We follow the CMS-approved compendia, but a medication is only approved when it follows a pathway.
c) We follow internal guidelines. No pathway is required.
d) We follow internal guidelines, with only specific pathways.
Respond Here and see what your colleagues are using too.
Want to see the results of our last survey regarding Medco's acquisition by Express Scripts?
Click Here. |
Editor's Pick
Osteoporosis
A review of current recommendations and emerging treatment options for osteoporosis. » Click here. |
|
Use of folic acid supplements in early pregnancy appeared to reduce the risk of severe language delay in children at age 3 years, according to the results of a study published October 12 in the Journal of the American Medical Association. » More |
|
The American Urological Association said the US Preventive Services Task Force is "doing a great disservice" to patients with its draft recommendations, published online October 7 in the Annals of Internal Medicine, regarding the prostate-specific antigen test. » More |
FDA ACTIONS
FDA has approved bupivacaine hydrochloride injection, USP (Sagent and Strides Arcolab), for use in surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures. » More |
|
FDA has approved exenatide (Byetta, Amylin and Eli Lilly) injection as an add-on therapy to insulin glargine in conjunction with diet and exercise for adults with type 2 diabetes. » More |
|
FDA has approved clobazam (Onfi, Lundbeck and Catalent Pharma Solutions) as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
